Medical Condition News

RSS

Perrigo introduces generic Zaditor

Perrigo Company today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™.

15 Mar 2010

Medtronic announces positive STOP AF clinical trial data at 59th American College of Cardiology session

Medtronic, Inc. today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during late-breaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta. The data showed superiority over anti-arrhythmic drugs, with 69.9 percent of patients with paroxysmal atrial fibrillation (PAF) treated with the Arctic Front® Cardiac CryoAblation Catheter System remaining free of atrial fibrillation (AF) one year after cryoablation, compared to 7.3 percent on drug therapy.

15 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

MannKind receives FDA Complete Response letter for AFREZZA NDA

MannKind Corporation today announced that it has received a Complete Response letter from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes mellitus for the control of hyperglycemia.

15 Mar 2010

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”

15 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

St. Jude Medical, Inc., a global medical device company, announced several updates to its PressureWire™ platform, including a new marketing agreement with Siemens Medical Solutions USA, for the wireless PressureWire™ Aeris and the availability of the next-generation of PressureWire™ Certus technology, at the American College of Cardiology and the Society of Interventional Radiology annual meetings.

15 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

Video-based supervision method helps caregiver offer better care for dementia patients

Astrid Andersen's master thesis at NHV has shown that the video-based supervision method, Marte Meo, used in dementia care has given the caregiver a concrete tool. It also has increased their consciousness and given them collective knowledge. They experience that they meet each patient's need in a better way.

15 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation are applauding the efforts of Pulmonary Fibrosis (PF) patients and family members for their work to convey to the FDA and an FDA Advisory Committee the sense of urgency and desperation regarding the disease and the lack of treatment options.

15 Mar 2010

Presence of plaque on abdominal CT scan: Strong predictor of coronary artery disease and mortality

The presence of plaque on an abdominal CT scan is a strong predictor of coronary artery disease and mortality, according to a Henry Ford Hospital study.

15 Mar 2010

Impact of tumor surgery on sexual function

Sexual problems are frequent after operations for carcinoma of the rectum. Christian Schmidt et al. describe the consequences for quality of life in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]: 123-30).

15 Mar 2010

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Scientists in Texas are reporting development of a first-of-its-kind cloth that releases nitric oxide gas - an advance toward making therapeutic socks for people with diabetes and a wrap to help preserve organs harvested for transplantation. The study is in ACS' Chemistry of Materials, a bi-weekly journal.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.

15 Mar 2010

Military surgeons update management of high-energy knee injuries

The ongoing wars in Iraq and Afghanistan have resulted in uniquely destructive patterns of combat injuries, including limb-threatening injuries to the knee. In the March special issue of Techniques in Knee Surgery military surgeons serving in Operation Iraqi Freedom and Operation Enduring Freedom share their experience with managing these high-energy injuries of the knee. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

15 Mar 2010

Medical Condition News

Perrigo introduces generic Zaditor

Medtronic announces positive STOP AF clinical trial data at 59th American College of Cardiology session

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

MannKind receives FDA Complete Response letter for AFREZZA NDA

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Metastatic melanoma: Involvement of immune system in response to PV-10 therapy

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

St. Jude Medical announces updates to PressureWire platform at ACC and SIR annual meetings

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Video-based supervision method helps caregiver offer better care for dementia patients

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

CPF, PFF applaud PF patients' efforts to plead with FDA Advisory Panel regarding lack of treatment options

Presence of plaque on abdominal CT scan: Strong predictor of coronary artery disease and mortality

Impact of tumor surgery on sexual function

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

NDA for BYDUREON: FDA issues complete response letter

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Military surgeons update management of high-energy knee injuries

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News